remdesivir

View All

recent-pharma-news-and-updates-for-gilead-novartis-lilly-innovent
Novartis’ COVID-19 deal; Shattered hopes for Remdesivir; Lilly’s R&D pact with Precision; Innovent’s Humira Biosimilar

Novartis bags Mesoblast's cell therapy, Remestemcel-L for COVID-19 ARDS The COVID-19 pandemic has put tremendous pressure on scientists to develop a safe and effective vaccine as early as possible. According to the WHO, there are currently more than 100 COVID-19 vaccine candidates under development, with several...

Find More

recent-pharma-news-and-updates-for-gilead-roche-celleron-f2g
Gilead’s remdesivir trials; F2G raises $60.8M; Cancer immunotherapy research updates; Celleron gains rights to Roche’s cancer drug

Researchers call out Gilead over the diversity of remdesivir trials Researchers have challenged the sponsors of COVID-19 clinical trials to run more diverse studies. The call follows an evaluation of Gilead’s remdesivir clinical trials, which found the studies that flunked to offer an equal representation of Bla...

Find More

Recent-pharma-news
FDA’s No to Intercept’s NASH Drug; Roche’s Phesgo gets approval; Gilead’s Remdesivir pricing

Intercept Pharmaceuticals receives a clear rejection from the FDA for its NASH drug, Obeticholic acid (OCA) Intercept Pharmaceuticals announced the issuance of a Complete Response Letter (CRL) by the FDA regarding the New Drug Application (NDA) for Obeticholic acid (OCA) for the treatment of fibrosis due to ...

Find More

pharma-news
Remdesivir accelerates for COVID-19 recovery; Merck pact with Almac; Pfizer, BioNTech finish dosing in; Taysha Gene Therapies for trials

Remdesivir of Gilead accelerates COVID-19 recovery Gilead Sciences' Remdesivir shows the first data from a placebo-controlled study. Remdesivir decreases recovery time for hospitalized COVID-19 patients by four days or 31% as published in a National Institutes of Health-sponsored study setting the drug against p...

Find More

covid-news
In the fight against COVID-19 – Lilly with Olumiant, Gilead with remdesivir, Rutgers with testing kit

Eli Lilly has announced to begin clinical trials of rheumatoid arthritis drug Olumiant to treat COVID-19 patients.  The company plans to explore the anti-inflammatory responses that were witnessed in rheumatoid arthritis patients, and how the drug – Olumiant – an oral JAK1/JAK2 inhibitor – might help in cur...

Find More

Pharma News
FDA permits COVID-19 treatment, Roche’s antibiotics pact, Moderna’s vaccine, FDA permits Remdesivir, ReCode needs USD 80 Million

FDA permits COVID-19 treatments with blood from survivors The FDA revealed the convalescent plasma use that is derived from the donated blood of people that have recovered from COVID-19 and that might have beneficial antibodies. It is being used as an investigational treatment for patients with severe cases of t...

Find More

Coronavirus
Wuhan Coronavirus: A global emergency

An outbreak of a mysterious viral infection, 2019-nCoV – coronavirus, has set the whole world on toes, claiming the lives of more than 800 people in China, surpassing the death toll caused from SARS, reports the Chinese government.  An infection with the symptoms more or less like pneumonia, known by the name ...

Find More